Skip to main content

Table 1 The characteristic of studies included in meta-analysis

From: The prognosis impact of hyperthermic intraperitoneal chemotherapy (HIPEC) plus cytoreductive surgery (CRS) in advanced ovarian cancer: the meta-analysis

Name Arm Original Country Mean age(year) Patients (Numbers) Stage OS (rate)
I-II III-IV
Ki Sung Ryu2004 Control group Primary South Korea 47.7 60 21 39 52.8%(5-year)
Experimental group 46.1 57 22 35 63.4%(5-year)
J. GORI 2005 Control group Primary Argentina 57.0 19 0 19 42.1%(5-year)
Experimental group 55.5 29 0 29 55.2%(5-year)
FranciscOC2009 Control group Recurrence Bulgaria 54 12 0 12 17% (5-year)
Experimental group 54 14 0 14 57% (5-year)
JIN HWI KIM 2010 Control group Primary South Korea 49 24 5 19 25%(8-year)
Experimental group 48 19 7 12 84.21%(8-year)
Rene Warschkow 2012 Control Group Primary or Recurrence Switzerland 65 90 56 35 38.3%(5-year)
Experimental group 58.9 21 17 4 72.5%(5-year)
Anna Fagotti 2012 Control Group Recurrence Italy 55 37 5 32 37.8%(5-year)
Experimental group 51 30 4 26 76.7%(5-year)
TAMAR SAFRA 2014 Control Group Recurrence Israel 54.3 84 7 76 45%(5-year)
Experimental group 54.3 27 2 25 79%(5-year)
Jean-Franc ̧ois Le Brun 2014 Control Group Recurrence France NR 19 1 18 19.4%(4-year)
Experimental group NR 23 2 21 75.6%(4-year)
Cascales-Campos, P. A2014 Control
Group
Primary Spain 57 35 0 35 NR
Experimental group 57 52 0 52 NR
J. Spiliotis 2015 Control Group Recurrence Greece 58.1 60 0 60 18%(3-year)
Experimental group 58.3 60 0 60 75%(3-year)
Glauco Baiocchi 2016 Control Group Recurrence Brazil 58.4 50 10 40 49.5%(5-year)
Experimental group 51.6 29 2 27 49.7%(5-year)
Alberto A. Mendivil 2017 Control Group Primary USA 62.9 69 0 69 75.3%(3-year)
Experimental group 59.8 69 0 69 82.6%(3-year)
W.J. van Driel 2018 Control Group Primary Netherlands 63 122 0 122 38%(5-year)
Experimental group 61 118 0 118 50%(5-year)